Histopathology 1 Flashcards
The standard slide
Routine is on formalin fixed, paraffin embedded tissue
Stained with haematoxylin and eosin
Examined by light microscopy
Most diagnostic practice on a microscope
Possible to scan sections and view on a remote web viewer
Special stains
Diastase periodic acid schiff for mucin
EVG for elastin, fibrosis
Masson fontana for melanin
Perl’s for iron
Von kossa for calcium
Ziehl neelsen for AFB
Giemsa for HP
Cytological changes in neoplasia
Increased N:C ratio
Irregular nuclear margin
Irregular distribution and texture of chromatin
Immunohistochemistry
Identifies specific proteins in tissue by using monoclonal antibodies
Important and useful in developing a differential diagnosis
Also gives prognostic information and informs treatment
The six tissues of origin
Epithelial (endothelial, synovial, mesothelial, meningeal)
Mesenchymal (fat, bone, cartilage, fibrous tissue, vessels)
Muscle
Neural (also melanocytes)
Germ line cells
Haematopoietic, lymphoid, blood
Epithelial markers
Cytokeratins
CK MNF 116
AE1/3
BerEP4
MOC-31
EMA
Mesothelial markers
Cytokeratins 5/6
HBME
Calretinin
Melanocytic markers
S100
MelanA
HMB45
Panmelanoma
Neuroendocrine markers
Chromogranin
CD56
Glial markers
GFAP
Mesenchymal markers
Vimentin
Desmin
Actin
Lymphoid markers
CD45
CD3
CD20
Vascular markers
CD31
Cytokeratins
The intermediate filaments of epithelial cells
Different expressed in different epithelia
CK7 positive CK20 positive carcinomas
Upper GI (adenocarcinoma)
Pancreatic (ductal)
Urothelial
CK 7 positive CK20 negative carcinomas
Breast
Ovarian
Pulmonary (adenoca)
Endometrial
Thyroid
CK7 negative CK20 positive carcinomas
Colorectal
Merkel cell
CK7 negative CK20 negative carcinomas
Prostatic
Hepatocellular
Renal cell
Adrenal cortical
Grading of neoplasms
Well differentiated (G1) Moderately differentiated (G2) Poorly differentiated (G3)
Increasingly
High grade
Low grade
Staging of neoplasms
How far the tumour has spread
TNM
FIGO (gynaecological)
AJCC (melanoma)
ENET (neuroendocrine)
Prognostic biomarkers
Breast BRCA1
Ovary BRCA1
Breast Her-2/ neu (worse)
Colon high frequency MSI (better)
NSCLC K-ras (worse)
NSCLC EGFR (worse)
Predictive biomarkers
RCC CAIX (response to IL-2)
KIT GIST (response to imatinib)
NSCLC EGFR (response to gefitinib)
Breast ER (response to tamoxifen)
Breast Her-2 (response to trastuzumab)
Gastric Her-2 (response to multiagent therapy)
NSCLC K-ras (less response to EGFR)
CRC K-ras (less response to EGFR)
NSCLC p53 (response to cisplatin)
Breast PTEN (reduced effectiveness to trastuzamib)
Lymphoma CD20 (response to anti CD20)